Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the
enzymes necessary for tumor cell growth